Biotech Values

[flatlander_60048]

This link suggests that orencia is patent protected until the end of 2019. Seems like there are better near term targets. Is their an obvious hole in the patent anyone is aware of.

This does raise an interesting point of discussion on what targets (other than those listed on MNTA's web site) that might be on the horizon. I kind of recall NVS mentioning on a conference call a couple years ago that the MNTA collaboration might extend to as many as 5 or 6 compounds. Assuming Copaxone and M-118 were under consideration at the time, what other targets might have been envisioned.

FL

http://wherepharmameets.bdmetrics.com/CPR-6043143-46262/GenericsWeb-Europe-Ltd/GenericsWeb-exposes-differences-between-Abatacept-generic-launch-contraints-in-EU-and-US.aspx